nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoteridol—Injection site reaction—Epirubicin—testicular cancer	0.0042	0.0042	CcSEcCtD
Gadoteridol—Erythema—Ifosfamide—testicular cancer	0.00417	0.00417	CcSEcCtD
Gadoteridol—Chest pain—Bleomycin—testicular cancer	0.00416	0.00416	CcSEcCtD
Gadoteridol—Discomfort—Bleomycin—testicular cancer	0.00411	0.00411	CcSEcCtD
Gadoteridol—Malaise—Dactinomycin—testicular cancer	0.00411	0.00411	CcSEcCtD
Gadoteridol—Salivary hypersecretion—Epirubicin—testicular cancer	0.0041	0.0041	CcSEcCtD
Gadoteridol—Urticaria—Chlorambucil—testicular cancer	0.00409	0.00409	CcSEcCtD
Gadoteridol—Abdominal pain—Chlorambucil—testicular cancer	0.00407	0.00407	CcSEcCtD
Gadoteridol—Body temperature increased—Chlorambucil—testicular cancer	0.00407	0.00407	CcSEcCtD
Gadoteridol—Pain—Vinblastine—testicular cancer	0.00403	0.00403	CcSEcCtD
Gadoteridol—Fluid retention—Epirubicin—testicular cancer	0.00401	0.00401	CcSEcCtD
Gadoteridol—Anaphylactic shock—Bleomycin—testicular cancer	0.00398	0.00398	CcSEcCtD
Gadoteridol—Oedema—Bleomycin—testicular cancer	0.00398	0.00398	CcSEcCtD
Gadoteridol—Feeling abnormal—Vinblastine—testicular cancer	0.00389	0.00389	CcSEcCtD
Gadoteridol—Injection site reaction—Doxorubicin—testicular cancer	0.00389	0.00389	CcSEcCtD
Gadoteridol—Ill-defined disorder—Ifosfamide—testicular cancer	0.00387	0.00387	CcSEcCtD
Gadoteridol—Tinnitus—Cisplatin—testicular cancer	0.00385	0.00385	CcSEcCtD
Gadoteridol—Rash maculo-papular—Epirubicin—testicular cancer	0.00384	0.00384	CcSEcCtD
Gadoteridol—Flushing—Cisplatin—testicular cancer	0.00383	0.00383	CcSEcCtD
Gadoteridol—Discomfort—Dactinomycin—testicular cancer	0.00383	0.00383	CcSEcCtD
Gadoteridol—Salivary hypersecretion—Doxorubicin—testicular cancer	0.0038	0.0038	CcSEcCtD
Gadoteridol—Hypersensitivity—Chlorambucil—testicular cancer	0.00379	0.00379	CcSEcCtD
Gadoteridol—Malaise—Ifosfamide—testicular cancer	0.00376	0.00376	CcSEcCtD
Gadoteridol—Abdominal pain—Vinblastine—testicular cancer	0.00373	0.00373	CcSEcCtD
Gadoteridol—Hypotension—Bleomycin—testicular cancer	0.00372	0.00372	CcSEcCtD
Gadoteridol—Oedema—Dactinomycin—testicular cancer	0.00372	0.00372	CcSEcCtD
Gadoteridol—Fluid retention—Doxorubicin—testicular cancer	0.00371	0.00371	CcSEcCtD
Gadoteridol—Pruritus—Chlorambucil—testicular cancer	0.00364	0.00364	CcSEcCtD
Gadoteridol—Cough—Ifosfamide—testicular cancer	0.00364	0.00364	CcSEcCtD
Gadoteridol—Convulsion—Ifosfamide—testicular cancer	0.00361	0.00361	CcSEcCtD
Gadoteridol—Hypertension—Ifosfamide—testicular cancer	0.0036	0.0036	CcSEcCtD
Gadoteridol—Erythema—Cisplatin—testicular cancer	0.0036	0.0036	CcSEcCtD
Gadoteridol—Paraesthesia—Bleomycin—testicular cancer	0.00358	0.00358	CcSEcCtD
Gadoteridol—Rash maculo-papular—Doxorubicin—testicular cancer	0.00355	0.00355	CcSEcCtD
Gadoteridol—Dyspnoea—Bleomycin—testicular cancer	0.00355	0.00355	CcSEcCtD
Gadoteridol—Chest pain—Ifosfamide—testicular cancer	0.00355	0.00355	CcSEcCtD
Gadoteridol—Diarrhoea—Chlorambucil—testicular cancer	0.00352	0.00352	CcSEcCtD
Gadoteridol—Flushing—Etoposide—testicular cancer	0.00351	0.00351	CcSEcCtD
Gadoteridol—Discomfort—Ifosfamide—testicular cancer	0.00351	0.00351	CcSEcCtD
Gadoteridol—Hypersensitivity—Vinblastine—testicular cancer	0.00348	0.00348	CcSEcCtD
Gadoteridol—Pain—Bleomycin—testicular cancer	0.00341	0.00341	CcSEcCtD
Gadoteridol—Oedema—Ifosfamide—testicular cancer	0.0034	0.0034	CcSEcCtD
Gadoteridol—Anaphylactic shock—Ifosfamide—testicular cancer	0.0034	0.0034	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Methotrexate—testicular cancer	0.00339	0.00339	CcSEcCtD
Gadoteridol—Tremor—Cisplatin—testicular cancer	0.00337	0.00337	CcSEcCtD
Gadoteridol—Ill-defined disorder—Cisplatin—testicular cancer	0.00334	0.00334	CcSEcCtD
Gadoteridol—Hyperhidrosis—Ifosfamide—testicular cancer	0.00329	0.00329	CcSEcCtD
Gadoteridol—Feeling abnormal—Bleomycin—testicular cancer	0.00328	0.00328	CcSEcCtD
Gadoteridol—Vomiting—Chlorambucil—testicular cancer	0.00327	0.00327	CcSEcCtD
Gadoteridol—Malaise—Cisplatin—testicular cancer	0.00324	0.00324	CcSEcCtD
Gadoteridol—Diarrhoea—Vinblastine—testicular cancer	0.00323	0.00323	CcSEcCtD
Gadoteridol—Dysgeusia—Etoposide—testicular cancer	0.00323	0.00323	CcSEcCtD
Gadoteridol—Hypotension—Ifosfamide—testicular cancer	0.00318	0.00318	CcSEcCtD
Gadoteridol—Pain—Dactinomycin—testicular cancer	0.00318	0.00318	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Epirubicin—testicular cancer	0.00317	0.00317	CcSEcCtD
Gadoteridol—Urticaria—Bleomycin—testicular cancer	0.00316	0.00316	CcSEcCtD
Gadoteridol—Body temperature increased—Bleomycin—testicular cancer	0.00315	0.00315	CcSEcCtD
Gadoteridol—Dizziness—Vinblastine—testicular cancer	0.00312	0.00312	CcSEcCtD
Gadoteridol—Convulsion—Cisplatin—testicular cancer	0.00312	0.00312	CcSEcCtD
Gadoteridol—Feeling abnormal—Dactinomycin—testicular cancer	0.00306	0.00306	CcSEcCtD
Gadoteridol—Nausea—Chlorambucil—testicular cancer	0.00306	0.00306	CcSEcCtD
Gadoteridol—Paraesthesia—Ifosfamide—testicular cancer	0.00306	0.00306	CcSEcCtD
Gadoteridol—Ill-defined disorder—Etoposide—testicular cancer	0.00306	0.00306	CcSEcCtD
Gadoteridol—Anxiety—Cisplatin—testicular cancer	0.00305	0.00305	CcSEcCtD
Gadoteridol—Dyspnoea—Ifosfamide—testicular cancer	0.00304	0.00304	CcSEcCtD
Gadoteridol—Discomfort—Cisplatin—testicular cancer	0.00303	0.00303	CcSEcCtD
Gadoteridol—Vomiting—Vinblastine—testicular cancer	0.003	0.003	CcSEcCtD
Gadoteridol—Malaise—Etoposide—testicular cancer	0.00297	0.00297	CcSEcCtD
Gadoteridol—Face oedema—Epirubicin—testicular cancer	0.00296	0.00296	CcSEcCtD
Gadoteridol—Headache—Vinblastine—testicular cancer	0.00296	0.00296	CcSEcCtD
Gadoteridol—Body temperature increased—Dactinomycin—testicular cancer	0.00294	0.00294	CcSEcCtD
Gadoteridol—Abdominal pain—Dactinomycin—testicular cancer	0.00294	0.00294	CcSEcCtD
Gadoteridol—Oedema—Cisplatin—testicular cancer	0.00294	0.00294	CcSEcCtD
Gadoteridol—Anaphylactic shock—Cisplatin—testicular cancer	0.00294	0.00294	CcSEcCtD
Gadoteridol—Hypersensitivity—Bleomycin—testicular cancer	0.00294	0.00294	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Doxorubicin—testicular cancer	0.00293	0.00293	CcSEcCtD
Gadoteridol—Cardiac arrest—Epirubicin—testicular cancer	0.00292	0.00292	CcSEcCtD
Gadoteridol—Pain—Ifosfamide—testicular cancer	0.00291	0.00291	CcSEcCtD
Gadoteridol—Loss of consciousness—Etoposide—testicular cancer	0.0029	0.0029	CcSEcCtD
Gadoteridol—Cough—Etoposide—testicular cancer	0.00288	0.00288	CcSEcCtD
Gadoteridol—Convulsion—Etoposide—testicular cancer	0.00285	0.00285	CcSEcCtD
Gadoteridol—Hypertension—Etoposide—testicular cancer	0.00284	0.00284	CcSEcCtD
Gadoteridol—Hyperhidrosis—Cisplatin—testicular cancer	0.00284	0.00284	CcSEcCtD
Gadoteridol—Pruritus—Bleomycin—testicular cancer	0.00282	0.00282	CcSEcCtD
Gadoteridol—Feeling abnormal—Ifosfamide—testicular cancer	0.00281	0.00281	CcSEcCtD
Gadoteridol—Chest pain—Etoposide—testicular cancer	0.00281	0.00281	CcSEcCtD
Gadoteridol—Nausea—Vinblastine—testicular cancer	0.0028	0.0028	CcSEcCtD
Gadoteridol—Discomfort—Etoposide—testicular cancer	0.00277	0.00277	CcSEcCtD
Gadoteridol—Hypotension—Cisplatin—testicular cancer	0.00274	0.00274	CcSEcCtD
Gadoteridol—Face oedema—Doxorubicin—testicular cancer	0.00274	0.00274	CcSEcCtD
Gadoteridol—Hypersensitivity—Dactinomycin—testicular cancer	0.00274	0.00274	CcSEcCtD
Gadoteridol—Urticaria—Ifosfamide—testicular cancer	0.0027	0.0027	CcSEcCtD
Gadoteridol—Cardiac arrest—Doxorubicin—testicular cancer	0.0027	0.0027	CcSEcCtD
Gadoteridol—Abdominal pain—Ifosfamide—testicular cancer	0.00269	0.00269	CcSEcCtD
Gadoteridol—Body temperature increased—Ifosfamide—testicular cancer	0.00269	0.00269	CcSEcCtD
Gadoteridol—Anaphylactic shock—Etoposide—testicular cancer	0.00269	0.00269	CcSEcCtD
Gadoteridol—Dysphagia—Epirubicin—testicular cancer	0.00265	0.00265	CcSEcCtD
Gadoteridol—Paraesthesia—Cisplatin—testicular cancer	0.00264	0.00264	CcSEcCtD
Gadoteridol—Dyspnoea—Cisplatin—testicular cancer	0.00262	0.00262	CcSEcCtD
Gadoteridol—Hyperhidrosis—Etoposide—testicular cancer	0.0026	0.0026	CcSEcCtD
Gadoteridol—Diarrhoea—Dactinomycin—testicular cancer	0.00254	0.00254	CcSEcCtD
Gadoteridol—Vomiting—Bleomycin—testicular cancer	0.00253	0.00253	CcSEcCtD
Gadoteridol—Hypotension—Etoposide—testicular cancer	0.00251	0.00251	CcSEcCtD
Gadoteridol—Rash—Bleomycin—testicular cancer	0.00251	0.00251	CcSEcCtD
Gadoteridol—Pain—Cisplatin—testicular cancer	0.00251	0.00251	CcSEcCtD
Gadoteridol—Dermatitis—Bleomycin—testicular cancer	0.00251	0.00251	CcSEcCtD
Gadoteridol—Hypersensitivity—Ifosfamide—testicular cancer	0.00251	0.00251	CcSEcCtD
Gadoteridol—Dysphagia—Doxorubicin—testicular cancer	0.00245	0.00245	CcSEcCtD
Gadoteridol—Sweating—Methotrexate—testicular cancer	0.00242	0.00242	CcSEcCtD
Gadoteridol—Feeling abnormal—Cisplatin—testicular cancer	0.00242	0.00242	CcSEcCtD
Gadoteridol—Paraesthesia—Etoposide—testicular cancer	0.00241	0.00241	CcSEcCtD
Gadoteridol—Pruritus—Ifosfamide—testicular cancer	0.00241	0.00241	CcSEcCtD
Gadoteridol—Dyspnoea—Etoposide—testicular cancer	0.0024	0.0024	CcSEcCtD
Gadoteridol—Nausea—Bleomycin—testicular cancer	0.00237	0.00237	CcSEcCtD
Gadoteridol—Vomiting—Dactinomycin—testicular cancer	0.00236	0.00236	CcSEcCtD
Gadoteridol—Rash—Dactinomycin—testicular cancer	0.00234	0.00234	CcSEcCtD
Gadoteridol—Diarrhoea—Ifosfamide—testicular cancer	0.00233	0.00233	CcSEcCtD
Gadoteridol—Body temperature increased—Cisplatin—testicular cancer	0.00232	0.00232	CcSEcCtD
Gadoteridol—Pain—Etoposide—testicular cancer	0.0023	0.0023	CcSEcCtD
Gadoteridol—Sweating—Epirubicin—testicular cancer	0.00227	0.00227	CcSEcCtD
Gadoteridol—Dizziness—Ifosfamide—testicular cancer	0.00225	0.00225	CcSEcCtD
Gadoteridol—Feeling abnormal—Etoposide—testicular cancer	0.00222	0.00222	CcSEcCtD
Gadoteridol—Nausea—Dactinomycin—testicular cancer	0.00221	0.00221	CcSEcCtD
Gadoteridol—Vomiting—Ifosfamide—testicular cancer	0.00216	0.00216	CcSEcCtD
Gadoteridol—Hypersensitivity—Cisplatin—testicular cancer	0.00216	0.00216	CcSEcCtD
Gadoteridol—Bradycardia—Epirubicin—testicular cancer	0.00216	0.00216	CcSEcCtD
Gadoteridol—Rash—Ifosfamide—testicular cancer	0.00215	0.00215	CcSEcCtD
Gadoteridol—Dermatitis—Ifosfamide—testicular cancer	0.00214	0.00214	CcSEcCtD
Gadoteridol—Urticaria—Etoposide—testicular cancer	0.00214	0.00214	CcSEcCtD
Gadoteridol—Rhinitis—Epirubicin—testicular cancer	0.00213	0.00213	CcSEcCtD
Gadoteridol—Abdominal pain—Etoposide—testicular cancer	0.00213	0.00213	CcSEcCtD
Gadoteridol—Body temperature increased—Etoposide—testicular cancer	0.00213	0.00213	CcSEcCtD
Gadoteridol—Tinnitus—Methotrexate—testicular cancer	0.00211	0.00211	CcSEcCtD
Gadoteridol—Sweating—Doxorubicin—testicular cancer	0.0021	0.0021	CcSEcCtD
Gadoteridol—Nausea—Ifosfamide—testicular cancer	0.00202	0.00202	CcSEcCtD
Gadoteridol—Diarrhoea—Cisplatin—testicular cancer	0.00201	0.00201	CcSEcCtD
Gadoteridol—Bradycardia—Doxorubicin—testicular cancer	0.002	0.002	CcSEcCtD
Gadoteridol—Hypersensitivity—Etoposide—testicular cancer	0.00198	0.00198	CcSEcCtD
Gadoteridol—Tinnitus—Epirubicin—testicular cancer	0.00198	0.00198	CcSEcCtD
Gadoteridol—Erythema—Methotrexate—testicular cancer	0.00197	0.00197	CcSEcCtD
Gadoteridol—Flushing—Epirubicin—testicular cancer	0.00197	0.00197	CcSEcCtD
Gadoteridol—Rhinitis—Doxorubicin—testicular cancer	0.00197	0.00197	CcSEcCtD
Gadoteridol—Dysgeusia—Methotrexate—testicular cancer	0.00193	0.00193	CcSEcCtD
Gadoteridol—Pruritus—Etoposide—testicular cancer	0.0019	0.0019	CcSEcCtD
Gadoteridol—Vomiting—Cisplatin—testicular cancer	0.00187	0.00187	CcSEcCtD
Gadoteridol—Rash—Cisplatin—testicular cancer	0.00185	0.00185	CcSEcCtD
Gadoteridol—Dermatitis—Cisplatin—testicular cancer	0.00185	0.00185	CcSEcCtD
Gadoteridol—Erythema—Epirubicin—testicular cancer	0.00185	0.00185	CcSEcCtD
Gadoteridol—Diarrhoea—Etoposide—testicular cancer	0.00184	0.00184	CcSEcCtD
Gadoteridol—Ill-defined disorder—Methotrexate—testicular cancer	0.00183	0.00183	CcSEcCtD
Gadoteridol—Tinnitus—Doxorubicin—testicular cancer	0.00183	0.00183	CcSEcCtD
Gadoteridol—Flushing—Doxorubicin—testicular cancer	0.00182	0.00182	CcSEcCtD
Gadoteridol—Dysgeusia—Epirubicin—testicular cancer	0.00181	0.00181	CcSEcCtD
Gadoteridol—Malaise—Methotrexate—testicular cancer	0.00178	0.00178	CcSEcCtD
Gadoteridol—Dizziness—Etoposide—testicular cancer	0.00178	0.00178	CcSEcCtD
Gadoteridol—Nausea—Cisplatin—testicular cancer	0.00174	0.00174	CcSEcCtD
Gadoteridol—Cough—Methotrexate—testicular cancer	0.00172	0.00172	CcSEcCtD
Gadoteridol—Ill-defined disorder—Epirubicin—testicular cancer	0.00171	0.00171	CcSEcCtD
Gadoteridol—Convulsion—Methotrexate—testicular cancer	0.00171	0.00171	CcSEcCtD
Gadoteridol—Vomiting—Etoposide—testicular cancer	0.00171	0.00171	CcSEcCtD
Gadoteridol—Erythema—Doxorubicin—testicular cancer	0.00171	0.00171	CcSEcCtD
Gadoteridol—Rash—Etoposide—testicular cancer	0.0017	0.0017	CcSEcCtD
Gadoteridol—Dermatitis—Etoposide—testicular cancer	0.00169	0.00169	CcSEcCtD
Gadoteridol—Headache—Etoposide—testicular cancer	0.00168	0.00168	CcSEcCtD
Gadoteridol—Chest pain—Methotrexate—testicular cancer	0.00168	0.00168	CcSEcCtD
Gadoteridol—Dysgeusia—Doxorubicin—testicular cancer	0.00167	0.00167	CcSEcCtD
Gadoteridol—Malaise—Epirubicin—testicular cancer	0.00167	0.00167	CcSEcCtD
Gadoteridol—Discomfort—Methotrexate—testicular cancer	0.00166	0.00166	CcSEcCtD
Gadoteridol—Syncope—Epirubicin—testicular cancer	0.00166	0.00166	CcSEcCtD
Gadoteridol—Loss of consciousness—Epirubicin—testicular cancer	0.00162	0.00162	CcSEcCtD
Gadoteridol—Cough—Epirubicin—testicular cancer	0.00161	0.00161	CcSEcCtD
Gadoteridol—Anaphylactic shock—Methotrexate—testicular cancer	0.00161	0.00161	CcSEcCtD
Gadoteridol—Convulsion—Epirubicin—testicular cancer	0.0016	0.0016	CcSEcCtD
Gadoteridol—Nausea—Etoposide—testicular cancer	0.0016	0.0016	CcSEcCtD
Gadoteridol—Hypertension—Epirubicin—testicular cancer	0.00159	0.00159	CcSEcCtD
Gadoteridol—Ill-defined disorder—Doxorubicin—testicular cancer	0.00159	0.00159	CcSEcCtD
Gadoteridol—Chest pain—Epirubicin—testicular cancer	0.00157	0.00157	CcSEcCtD
Gadoteridol—Anxiety—Epirubicin—testicular cancer	0.00157	0.00157	CcSEcCtD
Gadoteridol—Hyperhidrosis—Methotrexate—testicular cancer	0.00156	0.00156	CcSEcCtD
Gadoteridol—Discomfort—Epirubicin—testicular cancer	0.00155	0.00155	CcSEcCtD
Gadoteridol—Malaise—Doxorubicin—testicular cancer	0.00154	0.00154	CcSEcCtD
Gadoteridol—Dry mouth—Epirubicin—testicular cancer	0.00154	0.00154	CcSEcCtD
Gadoteridol—Syncope—Doxorubicin—testicular cancer	0.00153	0.00153	CcSEcCtD
Gadoteridol—Oedema—Epirubicin—testicular cancer	0.00151	0.00151	CcSEcCtD
Gadoteridol—Anaphylactic shock—Epirubicin—testicular cancer	0.00151	0.00151	CcSEcCtD
Gadoteridol—Hypotension—Methotrexate—testicular cancer	0.00151	0.00151	CcSEcCtD
Gadoteridol—Loss of consciousness—Doxorubicin—testicular cancer	0.0015	0.0015	CcSEcCtD
Gadoteridol—Cough—Doxorubicin—testicular cancer	0.00149	0.00149	CcSEcCtD
Gadoteridol—Shock—Epirubicin—testicular cancer	0.00148	0.00148	CcSEcCtD
Gadoteridol—Convulsion—Doxorubicin—testicular cancer	0.00148	0.00148	CcSEcCtD
Gadoteridol—Hypertension—Doxorubicin—testicular cancer	0.00148	0.00148	CcSEcCtD
Gadoteridol—Hyperhidrosis—Epirubicin—testicular cancer	0.00146	0.00146	CcSEcCtD
Gadoteridol—Chest pain—Doxorubicin—testicular cancer	0.00145	0.00145	CcSEcCtD
Gadoteridol—Anxiety—Doxorubicin—testicular cancer	0.00145	0.00145	CcSEcCtD
Gadoteridol—Paraesthesia—Methotrexate—testicular cancer	0.00145	0.00145	CcSEcCtD
Gadoteridol—Discomfort—Doxorubicin—testicular cancer	0.00144	0.00144	CcSEcCtD
Gadoteridol—Dyspnoea—Methotrexate—testicular cancer	0.00144	0.00144	CcSEcCtD
Gadoteridol—Dry mouth—Doxorubicin—testicular cancer	0.00142	0.00142	CcSEcCtD
Gadoteridol—Hypotension—Epirubicin—testicular cancer	0.00141	0.00141	CcSEcCtD
Gadoteridol—Oedema—Doxorubicin—testicular cancer	0.00139	0.00139	CcSEcCtD
Gadoteridol—Anaphylactic shock—Doxorubicin—testicular cancer	0.00139	0.00139	CcSEcCtD
Gadoteridol—Pain—Methotrexate—testicular cancer	0.00138	0.00138	CcSEcCtD
Gadoteridol—Shock—Doxorubicin—testicular cancer	0.00137	0.00137	CcSEcCtD
Gadoteridol—Paraesthesia—Epirubicin—testicular cancer	0.00135	0.00135	CcSEcCtD
Gadoteridol—Hyperhidrosis—Doxorubicin—testicular cancer	0.00135	0.00135	CcSEcCtD
Gadoteridol—Dyspnoea—Epirubicin—testicular cancer	0.00134	0.00134	CcSEcCtD
Gadoteridol—Feeling abnormal—Methotrexate—testicular cancer	0.00133	0.00133	CcSEcCtD
Gadoteridol—Hypotension—Doxorubicin—testicular cancer	0.0013	0.0013	CcSEcCtD
Gadoteridol—Pain—Epirubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Gadoteridol—Urticaria—Methotrexate—testicular cancer	0.00128	0.00128	CcSEcCtD
Gadoteridol—Abdominal pain—Methotrexate—testicular cancer	0.00127	0.00127	CcSEcCtD
Gadoteridol—Body temperature increased—Methotrexate—testicular cancer	0.00127	0.00127	CcSEcCtD
Gadoteridol—Paraesthesia—Doxorubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Gadoteridol—Dyspnoea—Doxorubicin—testicular cancer	0.00124	0.00124	CcSEcCtD
Gadoteridol—Feeling abnormal—Epirubicin—testicular cancer	0.00124	0.00124	CcSEcCtD
Gadoteridol—Urticaria—Epirubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Gadoteridol—Pain—Doxorubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Gadoteridol—Abdominal pain—Epirubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Gadoteridol—Body temperature increased—Epirubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Gadoteridol—Hypersensitivity—Methotrexate—testicular cancer	0.00119	0.00119	CcSEcCtD
Gadoteridol—Feeling abnormal—Doxorubicin—testicular cancer	0.00115	0.00115	CcSEcCtD
Gadoteridol—Pruritus—Methotrexate—testicular cancer	0.00114	0.00114	CcSEcCtD
Gadoteridol—Hypersensitivity—Epirubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Gadoteridol—Urticaria—Doxorubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Gadoteridol—Abdominal pain—Doxorubicin—testicular cancer	0.0011	0.0011	CcSEcCtD
Gadoteridol—Body temperature increased—Doxorubicin—testicular cancer	0.0011	0.0011	CcSEcCtD
Gadoteridol—Diarrhoea—Methotrexate—testicular cancer	0.0011	0.0011	CcSEcCtD
Gadoteridol—Pruritus—Epirubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Gadoteridol—Dizziness—Methotrexate—testicular cancer	0.00107	0.00107	CcSEcCtD
Gadoteridol—Diarrhoea—Epirubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Gadoteridol—Hypersensitivity—Doxorubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Gadoteridol—Vomiting—Methotrexate—testicular cancer	0.00102	0.00102	CcSEcCtD
Gadoteridol—Rash—Methotrexate—testicular cancer	0.00102	0.00102	CcSEcCtD
Gadoteridol—Dermatitis—Methotrexate—testicular cancer	0.00101	0.00101	CcSEcCtD
Gadoteridol—Headache—Methotrexate—testicular cancer	0.00101	0.00101	CcSEcCtD
Gadoteridol—Dizziness—Epirubicin—testicular cancer	0.000997	0.000997	CcSEcCtD
Gadoteridol—Pruritus—Doxorubicin—testicular cancer	0.000987	0.000987	CcSEcCtD
Gadoteridol—Vomiting—Epirubicin—testicular cancer	0.000958	0.000958	CcSEcCtD
Gadoteridol—Nausea—Methotrexate—testicular cancer	0.000957	0.000957	CcSEcCtD
Gadoteridol—Diarrhoea—Doxorubicin—testicular cancer	0.000954	0.000954	CcSEcCtD
Gadoteridol—Rash—Epirubicin—testicular cancer	0.00095	0.00095	CcSEcCtD
Gadoteridol—Dermatitis—Epirubicin—testicular cancer	0.00095	0.00095	CcSEcCtD
Gadoteridol—Headache—Epirubicin—testicular cancer	0.000944	0.000944	CcSEcCtD
Gadoteridol—Dizziness—Doxorubicin—testicular cancer	0.000922	0.000922	CcSEcCtD
Gadoteridol—Nausea—Epirubicin—testicular cancer	0.000895	0.000895	CcSEcCtD
Gadoteridol—Vomiting—Doxorubicin—testicular cancer	0.000887	0.000887	CcSEcCtD
Gadoteridol—Rash—Doxorubicin—testicular cancer	0.000879	0.000879	CcSEcCtD
Gadoteridol—Dermatitis—Doxorubicin—testicular cancer	0.000879	0.000879	CcSEcCtD
Gadoteridol—Headache—Doxorubicin—testicular cancer	0.000874	0.000874	CcSEcCtD
Gadoteridol—Nausea—Doxorubicin—testicular cancer	0.000828	0.000828	CcSEcCtD
